NCT02493582

The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR

The Randomized, Controlled Clinical Trial of Apatinib Plus CIK as the Third Line Therapy for Lung Adenocarcinoma Patients With Wild-Type EGFR

• Status: Active Not Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 400 (estimated)
• Sponsor: The First People's Hospital of Changzhou · Academic / Other
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to evaluate the safety and efficacy of Apatinib combined with cytokine-induced killer cell (CIK) vs Apatinib alone as the third line therapy for advanced lung adenocarcinoma patients with wild-type EGFR

Detailed description

400 patients with stage IIIB \& IV lung adenocarcinoma who had received surgery and chemotherapy,will be randomly divided into group A（Apatinib plus CIK treatment ) or group B（Apatinib), and the randomize ratio will be 1:1. Patients in group A will receive 3 cycles of CIK treatment (every 1 year) and Apatinib (continuous).Patients in group B will receive only Apatinib (continuous) .

Conditions

• Adenocarcinoma of Lung

Interventions

Type	Name	Description
BIOLOGICAL	Cytokine-Induced Killer Cells	CIKs are used with Apatinib to treat lung adenocarcinoma patients with wild-type EGFR
DRUG	Apatinib	Advanced lung adenocarcinoma patients with wild-type EGFR take Apatinib 850mg qd by mouth.

Timeline

• Start date: 2015-07-01
• Primary completion: 2030-07-01
• Completion: 2033-07-01
• First posted: 2015-07-09
• Last updated: 2016-02-05